Kamada (KMDA) Competitors $7.76 +0.01 (+0.13%) Closing price 04:00 PM EasternExtended Trading$7.69 -0.07 (-0.90%) As of 05:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KMDA vs. ARQT, ADPT, IMCR, SPRY, EWTX, SDGR, BHVN, ETNB, ANIP, and JANXShould you be buying Kamada stock or one of its competitors? The main competitors of Kamada include Arcutis Biotherapeutics (ARQT), Adaptive Biotechnologies (ADPT), Immunocore (IMCR), ARS Pharmaceuticals (SPRY), Edgewise Therapeutics (EWTX), Schrodinger (SDGR), Biohaven (BHVN), 89BIO (ETNB), ANI Pharmaceuticals (ANIP), and Janux Therapeutics (JANX). These companies are all part of the "pharmaceutical products" industry. Kamada vs. Its Competitors Arcutis Biotherapeutics Adaptive Biotechnologies Immunocore ARS Pharmaceuticals Edgewise Therapeutics Schrodinger Biohaven 89BIO ANI Pharmaceuticals Janux Therapeutics Kamada (NASDAQ:KMDA) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership. Do analysts prefer KMDA or ARQT? Kamada currently has a consensus price target of $14.67, indicating a potential upside of 89.00%. Arcutis Biotherapeutics has a consensus price target of $18.80, indicating a potential upside of 36.73%. Given Kamada's higher probable upside, equities research analysts clearly believe Kamada is more favorable than Arcutis Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kamada 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Arcutis Biotherapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Does the media favor KMDA or ARQT? In the previous week, Arcutis Biotherapeutics had 4 more articles in the media than Kamada. MarketBeat recorded 7 mentions for Arcutis Biotherapeutics and 3 mentions for Kamada. Arcutis Biotherapeutics' average media sentiment score of 1.03 beat Kamada's score of 0.75 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kamada 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcutis Biotherapeutics 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, KMDA or ARQT? Kamada has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500. Comparatively, Arcutis Biotherapeutics has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500. Which has stronger earnings and valuation, KMDA or ARQT? Kamada has higher earnings, but lower revenue than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKamada$160.95M2.77$14.46M$0.2926.76Arcutis Biotherapeutics$196.54M8.34-$140.04M-$1.04-13.22 Is KMDA or ARQT more profitable? Kamada has a net margin of 9.60% compared to Arcutis Biotherapeutics' net margin of -60.95%. Kamada's return on equity of 6.31% beat Arcutis Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kamada9.60% 6.31% 4.43% Arcutis Biotherapeutics -60.95%-80.66%-32.94% Do insiders & institutionals hold more shares of KMDA or ARQT? 20.4% of Kamada shares are held by institutional investors. 36.1% of Kamada shares are held by insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryKamada beats Arcutis Biotherapeutics on 8 of the 15 factors compared between the two stocks. Get Kamada News Delivered to You Automatically Sign up to receive the latest news and ratings for KMDA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KMDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KMDA vs. The Competition Export to ExcelMetricKamadaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$445.66M$2.87B$5.52B$8.85BDividend YieldN/A2.70%5.36%4.13%P/E Ratio26.7221.1726.3119.76Price / Sales2.77263.83409.02110.15Price / Cash15.7741.2925.8827.49Price / Book1.727.237.915.36Net Income$14.46M-$55.05M$3.15B$248.34M7 Day Performance-2.39%-0.74%0.95%1.25%1 Month Performance13.78%6.27%5.25%5.41%1 Year Performance60.66%0.19%32.63%18.06% Kamada Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KMDAKamada4.055 of 5 stars$7.76+0.1%$14.67+89.0%+56.3%$445.66M$160.95M26.72360ARQTArcutis Biotherapeutics2.1896 of 5 stars$14.40+4.2%$18.80+30.6%+50.8%$1.65B$196.54M-13.85150Positive NewsADPTAdaptive Biotechnologies3.2951 of 5 stars$10.56+1.7%$10.57+0.1%+221.8%$1.58B$178.96M-11.00790Gap DownIMCRImmunocore2.4477 of 5 stars$31.12-0.7%$58.89+89.2%-7.4%$1.57B$310.20M-72.37320SPRYARS Pharmaceuticals3.0867 of 5 stars$16.57+4.9%$31.00+87.1%+105.1%$1.55B$89.15M-103.5690Analyst UpgradeEWTXEdgewise Therapeutics3.47 of 5 stars$14.18-0.8%$39.78+180.5%-27.2%$1.50BN/A-9.1560News CoverageAnalyst ForecastSDGRSchrodinger2.6082 of 5 stars$20.35-0.5%$32.80+61.2%+4.0%$1.50B$207.54M-7.74790BHVNBiohaven2.7829 of 5 stars$14.44-0.2%$58.46+305.0%-59.3%$1.48BN/A-1.54239ETNB89BIO2.1135 of 5 stars$10.00-0.8%$26.43+164.3%+22.6%$1.47BN/A-2.9640ANIPANI Pharmaceuticals4.2391 of 5 stars$66.03+0.7%$80.13+21.3%+2.5%$1.42B$614.38M-51.99600JANXJanux Therapeutics2.2692 of 5 stars$22.88-3.1%$95.25+316.3%-44.9%$1.40B$10.59M-16.8230 Related Companies and Tools Related Companies Arcutis Biotherapeutics Alternatives Adaptive Biotechnologies Alternatives Immunocore Alternatives ARS Pharmaceuticals Alternatives Edgewise Therapeutics Alternatives Schrodinger Alternatives Biohaven Alternatives 89BIO Alternatives ANI Pharmaceuticals Alternatives Janux Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KMDA) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kamada Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kamada With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
